Brought to you by 
Xoma gets US rights to Servier's perindopril franchise, including Aceon
30 Jan 2023
Executive Summary
Xoma Corp. (antibodies) has licensed exclusive US rights to Servier SA’s perindopril franchise, including the branded ACE inhibitor Aceon (perindopril erbumine) for hypertension, and three fixed-dose combinations (FDC; the drug candidates combine perindopril with an active ingredient) that are under patent until 2023. Xoma gets exclusive US rights to the first FDC, which combines perindopril with the calcium channel blocker amlodipine, and options to the other two FDCs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Xoma gets US rights to Servier's perindopril franchise, including Aceon
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice